Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  CAS  PubMed  Google Scholar 

Horinouchi H, Kusumoto M, Yatabe Y et al (2022) Lung cancer in Japan. J Thorac Oncol 17(3):353–361. https://doi.org/10.1016/j.jtho.2021.11.020

Article  PubMed  Google Scholar 

Sobue T (2000) A case-control study for evaluating lung cancer screening in Japan. Cancer 89(11 Suppl):2392–2396. https://doi.org/10.1002/1097-0142(20001201)89:11+%3c2392::aid-cncr13%3e3.3.co;2-a

Article  CAS  PubMed  Google Scholar 

Punekar SR, Shum E, Grello CM et al (2022) Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Front Oncol 12:877594. https://doi.org/10.3389/fonc.2022.877594

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chirieac LR, Dacic S (2010) Targeted therapies in lung cancer. Surg Pathol Clin 3(1):71–82. https://doi.org/10.1016/j.path.2010.04.001

Article  PubMed  PubMed Central  Google Scholar 

Collaborators GBDCoD (2024) Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403(10440):2100–2132. https://doi.org/10.1016/S0140-6736(24)00367-2

Article  Google Scholar 

Nakatani H (2019) Population aging in Japan: policy transformation, sustainable development goals, universal health coverage, and social determinates of health. Glob Health Med 1(1):3–10. https://doi.org/10.35772/ghm.2019.01011

Article  CAS  PubMed Central  Google Scholar 

Spiro SG, Silvestri GA (2005) One hundred years of lung cancer. Am J Respir Crit Care Med 172(5):523–529. https://doi.org/10.1164/rccm.200504-531OE

Article  Google Scholar 

Redpath TW (1997) MRI developments in perspective. Br J Radiol. https://doi.org/10.1259/bjr.1997.0010

Article  Google Scholar 

Townsend DW (2008) Combined positron emission tomography-computed tomography: the historical perspective. Semin Ultrasound CT MR 29(4):232–235. https://doi.org/10.1053/j.sult.2008.05.006

Article  PubMed  PubMed Central  Google Scholar 

Urikura A, Yoshida T, Matsubara K et al (2023) Number of computed tomography scanners and regional disparities based on population and medical resources in Japan. Radiol Phys Technol 16(3):355–365. https://doi.org/10.1007/s12194-023-00725-2

Article  PubMed  Google Scholar 

Huang F, Pan B, Wu J et al (2017) Relationship between exposure to PM25 and lung cancer incidence and mortality: A meta-analysis. Oncotarget 8(26):43322–43331. https://doi.org/10.18632/oncotarget.17313

Article  PubMed  PubMed Central  Google Scholar 

Thandra KC, Barsouk A, Saginala K et al (2021) Epidemiology of lung cancer. Contemp Oncol (Pozn) 25(1):45–52. https://doi.org/10.5114/wo.2021.103829

Article  CAS  PubMed  Google Scholar 

Nagasawa T, Saito J, Odawara M et al (2022) Smoking cessation interventions and implementations in Japan: a study protocol for a scoping review and supplemental survey. BMJ Open 12(12):e063912. https://doi.org/10.1136/bmjopen-2022-063912

Article  PubMed  PubMed Central  Google Scholar 

Tabuchi T, Nakamura M, Nakayama T et al (2016) Tobacco price increase and smoking cessation in japan, a developed country with affordable tobacco: a national population-based observational study. J Epidemiol 26(1):14–21. https://doi.org/10.2188/jea.JE20140183

Article  PubMed  PubMed Central  Google Scholar 

Nguyen PT, Katanoda K, Saito E et al (2022) Trends in lung cancer incidence by gender, histological type and stage at diagnosis in Japan, 1993 to 2015: A multiple imputation approach. Int J Cancer 151(1):20–32. https://doi.org/10.1002/ijc.33962

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18(2):317–323. https://doi.org/10.1093/annonc/mdl377

Article  CAS  PubMed  Google Scholar 

Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98. https://doi.org/10.1056/NEJMoa011954

Article  CAS  PubMed  Google Scholar 

Kubota K, Watanabe K, Kunitoh H et al (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22(2):254–261. https://doi.org/10.1200/jco.2004.06.114

Article  CAS  PubMed  Google Scholar 

Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866–2874. https://doi.org/10.1200/JCO.2010.33.4235

Article  CAS  PubMed  Google Scholar 

Inoue A, Kobayashi K, Maemondo M et al (2013) Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. https://doi.org/10.1093/annonc/mds214

Article  PubMed  Google Scholar 

Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639. https://doi.org/10.1056/NEJMoa1507643

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135. https://doi.org/10.1056/NEJMoa1504627

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saito M, Shiraishi K, Kunitoh H et al (2016) Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci 107(6):713–720. https://doi.org/10.1111/cas.12941

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramalingam S, Gray J, Ohe Y et al (2019) Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. Ann Oncol 30:v914–v915

Article  Google Scholar 

Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer. N Engl J Med 377(9):829–838

Article  CAS  Google Scholar 

Moro-Sibilot D, Cozic N, Pérol M et al (2019) Crizotinib in c-MET-or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol 30(12):1985–1991

Article  CAS  PubMed  Google Scholar 

Planchard D, Besse B, Groen HJ et al (2016) Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17(7):984–993

Article